BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 36248808)

  • 21. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity.
    Yan Y; Huang L; Liu Y; Yi M; Chu Q; Jiao D; Wu K
    J Hematol Oncol; 2022 Aug; 15(1):104. PubMed ID: 35948909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.
    Liu HY; Pedros C; Kong KF; Canonigo-Balancio AJ; Xue W; Altman A
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34588224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-coding RNA in tumor-infiltrating regulatory T cells formation and associated immunotherapy.
    Ma Y; Xu X; Wang H; Liu Y; Piao H
    Front Immunol; 2023; 14():1228331. PubMed ID: 37671150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells.
    Beauford SS; Kumari A; Garnett-Benson C
    BMC Immunol; 2020 Apr; 21(1):18. PubMed ID: 32299365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
    Mempel TR; Krappmann D
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
    Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
    Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy.
    Tay C; Tanaka A; Sakaguchi S
    Cancer Cell; 2023 Mar; 41(3):450-465. PubMed ID: 36917950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8
    Liu C; Chikina M; Deshpande R; Menk AV; Wang T; Tabib T; Brunazzi EA; Vignali KM; Sun M; Stolz DB; Lafyatis RA; Chen W; Delgoffe GM; Workman CJ; Wendell SG; Vignali DAA
    Immunity; 2019 Aug; 51(2):381-397.e6. PubMed ID: 31350177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
    J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
    Liu J; Zhang B; Zhang G; Shang D
    Front Immunol; 2024; 15():1345838. PubMed ID: 38449875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer.
    Chuckran CA; Cillo AR; Moskovitz J; Overacre-Delgoffe A; Somasundaram AS; Shan F; Magnon GC; Kunning SR; Abecassis I; Zureikat AH; Luketich J; Pennathur A; Sembrat J; Rojas M; Merrick DT; Taylor SE; Orr B; Modugno F; Buckanovich R; Schoen RE; Kim S; Duvvuri U; Zeh H; Edwards R; Kirkwood JM; Coffman L; Ferris RL; Bruno TC; Vignali DAA
    Sci Transl Med; 2021 Dec; 13(623):eabf8495. PubMed ID: 34878821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic targeting of regulatory T cells in cancer.
    Shan F; Somasundaram A; Bruno TC; Workman CJ; Vignali DAA
    Trends Cancer; 2022 Nov; 8(11):944-961. PubMed ID: 35853825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
    Freeman ZT; Nirschl TR; Hovelson DH; Johnston RJ; Engelhardt JJ; Selby MJ; Kochel CM; Lan RY; Zhai J; Ghasemzadeh A; Gupta A; Skaist AM; Wheelan SJ; Jiang H; Pearson AT; Snyder LA; Korman AJ; Tomlins SA; Yegnasubramanian S; Drake CG
    J Clin Invest; 2020 Mar; 130(3):1405-1416. PubMed ID: 32015231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory cells and the effect of cancer immunotherapy.
    Iglesias-Escudero M; Arias-González N; Martínez-Cáceres E
    Mol Cancer; 2023 Feb; 22(1):26. PubMed ID: 36739406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.
    Spasevska I; Sharma A; Steen CB; Josefsson SE; Blaker YN; Kolstad A; Rustad EH; Meyer S; Isaksen K; Chellappa S; Kushekhar K; Beiske K; Førsund MS; Spetalen S; Holte H; Østenstad B; Brodtkorb M; Kimby E; Olweus J; Taskén K; Newman AM; Lorenz S; Smeland EB; Alizadeh AA; Huse K; Myklebust JH
    Blood Adv; 2023 Dec; 7(23):7216-7230. PubMed ID: 37695745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
    Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
    Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
    Saleh R; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.